Omeprazole Market Share

  • Report ID: 2477
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Omeprazole Market Share

North American Market Forecast

North America omeprazole market is anticipated to hold the largest share of 59.3% during the forecast period. In 2020 the region experienced the prevalence of H. pylori infection which causes ulcers. Additionally, peptic ulcers are prominent in the US, around 4.5 million individuals are affected yearly. Also, about 10% of the US population is affected by duodenal ulcers. For example, there is an online service that helps people save around 80% on their prescription costs by working with large pharmacies in the US. These key factors are bolstering the market growth of Omeprazole in the region.

APAC Market Statistics

Asia Pacific to hold a share of 28.6% by 2036. Market growth in the region is driven by greater awareness amongst target audiences about treating this condition, growing incidences, and intensified focus of key market players to increase their product portfolio. Vonoprazan, a product that is FDA-cleared for the treatment of gastroesophageal reflux disease by Phantom Pharmaceutics, was made available to Japanese consumers and another Asian country in March 2022. In addition, with the increased demand for gastroesophageal disease treatment in the Asia region, a number of players have been expanding their presence there.

Research Nester
Omeprazole Market Growth
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2477
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of omeprazole is estimated at USD 1.12 Billion.

The omeprazole market size was valued at USD 1.06 Billion in 2023 and is expected to cross USD 2.38 Billion by the end of 2036, expanding at more than 6.4% CAGR during the forecast period i.e., between 2024-2036. Increasing cases of gastroesophageal reflux, increasing awareness among people, and increasing prevalence of duodenal ulcers.

Asia Pacific industry will hold a share of 28.6% by 2036, driven by greater awareness amongst target audiences about treating this condition, growing incidences, and intensified focus of key players to increase their product portfolio in the region.

Boehringer Ingelheim, AstraZeneca Plc., Azurity Pharma, Perrigo Company Plc., Salix pharmaceuticals
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample